degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
spongostan spugna di gelatina emostatica riassorbibile
spongostan spugna di gelatina emostatica riassorbibile
spongostan polvere di gelatina emostatica riassorbibile
clexane 6.000 anti-xa i.e./0,6 ml raztopina za injiciranje v napolnjeni injkecijski brizgi
raztopina za injiciranje - enoksaparin
clexane 9.000 anti-xa i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
raztopina za injiciranje - enoksaparin
clexane 4.000 anti-xa i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
raztopina za injiciranje - enoksaparin
clexane 8.000 anti-xa i.e./0,8 ml raztopina za injiciranje v napolnjeni injkecijski brizgi
raztopina za injiciranje - enoksaparin
firmagon
ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.